CCO Medical Specialties Podcast

Listen as Michael S. Benninger, MD, describes his approach to the diagnosis and management of chronic cough and refractory chronic cough in the context of a clinically relevant case.PresenterMichael S. Benninger, MDProfessor of Otolaryngology-Head and Neck SurgeryLerner College of MedicineThe Cleveland ClinicPresident, International Association of PhonosurgeryCleveland, OhioLink to full program:https://bit.ly/4kweynG

Listen in as Joseph Kim, MD, MPH, MBA, and Colten Bracken, MD, FAAFP, discuss how to integrate comprehensive diabetes management to improve the quality of their obesity care delivery, including: Documenting obesity as a diagnosis for patients with diabetes when appropriateStreamlining processes to ensure patients return for follow-upDedicating a care manager to initiate patient outreachImplementing pharmacotherapy strategies to help patients control their A1C and achieve weight loss simultaneously.PresentersJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaColten Bracken, MD, FAAFPBoard of Directors for RHAU & UAFPOwner/Medical DirectorMain Street Family Medicine, PLLCEnterprise, UtahLink to full program: https://bit.ly/3IBFZi5

In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH​, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:Steatotic liver disease and PBCVibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBCPPAR agonists and IBATs for PBC treatment Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United Kingdom Link to full program: https://bit.ly/44ySoL3Follow along with the slides: https://bit.ly/3IvwQrjGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Daniel C. Butler, MD, and Shawn G. Kwatra, MD, discuss the practical considerations for using IL-13 inhibitors to treat patients with moderate to severe atopic dermatitis, including:Patient candidacy considerationsTreatment advancement strategies that go beyond topical therapiesThe importance of patient-centered care that address patients' fears and needsA detailed patient case to highlight take home pointsPresenterDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaShawn G. Kwatra, MD​Dr. Joseph W. Burnett Endowed Professor and Chair ​Department of Dermatology​University of Maryland School of Medicine​Baltimore, MarylandProgram page:https://bit.ly/4kTP04D

In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:The available biologic therapies that specifically target IL-13Where these agents fall in the 2024 American Academy of Dermatology treatment algorithmHow these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitorsA detailed patient case to highlight take home pointsPresenterAndrew F. Alexis, MD, MPH​Professor of Clinical Dermatology​Weill Cornell Medical College ​New York, New YorkDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaShawn G. Kwatra, MD​Dr. Joseph W. Burnett Endowed Professor and Chair ​Department of Dermatology​University of Maryland School of Medicine​Baltimore, MarylandProgram page:https://bit.ly/4kTP04D

Listen in as Joseph Kim, MD, MPH, MBA; Manish Shah, MD; Martha Grugel, MA, discuss how they manage the prior authorization process for antiobesity agents to improve the quality of their care delivery, including:The information to collect during patient visitsThe available resources to help you submit prior authorizationsThe supporting documents that are often necessary to accompany prior authorizationsHow to address denials and appealsWhen to access manufacturer-based or foundation-based financial assistancePresentersJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaManish Shah, MDClinical Associate Faculty MS1 PreceptorUniversity of Florida College of MedicineGainesville, FloridaMartha Grugel, MAMedical AssistantWesley Chapel, FloridaLink to full program: https://bit.ly/45P0v8z

In this episode, Andrew F. Alexis, MD, MPH, and Daniel C. Butler, MD, discuss the immunopathogenesis and role of IL-13 in atopic dermatitis (AD), including:Contributors to epidermal barrier dysfunction (eg, environmental triggers)IL-13 as a key cytokine in AD pathogenesisTargeted AD therapies that inhibit IL-13A detailed patient case to highlight take-home pointsPresenterAndrew F. Alexis, MD, MPH​Professor of Clinical Dermatology​Weill Cornell Medical College ​New York, New YorkDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaProgram page: https://bit.ly/4kTP04D

In this podcast, Anne E. O'Donnell, MD, discusses the latest advances and treatment strategies for patients with non–cystic fibrosis bronchiectasis (NCFBE), including:Airway clearance as a foundation of NCFBE managementStrategies to address inflammation and exacerbationsEmerging therapies in clinical developmentHow to individualize treatment to NCFBE phenotypes and endotypesPresenterAnne E. O'Donnell, MDProfessor of MedicineThe Nehemiah and Naomi Cohen Chair in Pulmonology Disease ResearchChief, Division of Pulmonary, Critical Care and Sleep MedicineGeorgetown University Medical CenterWashington, DCProgram page:https://bit.ly/4mZbYsm

In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including:The emerging role of mineralocorticoid receptor antagonists in HF careFinerenone's efficacy in reducing composite cardiovascular death and worsening HF events Why safety must be monitored, especially considering hyperkalemia riskWhere HF guideline recommendations lack compared with the current evidence PresenterTy J. Gluckman, MD, MHAMedical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)Providence Heart InstituteProvidence Health SystemPortland, OregonProgram page: https://bit.ly/448XcH0

In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including:The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection)Cough as the most significant symptom and burdenImaging bronchiectasis with classic and inflammatory findingsDifferentiating the causes of NCFBE to inform patient carePresentersBrett M. Elicker, MDProfessor of Clinical RadiologyChief, Cardiothoracic Imaging DivisionDepartment of Radiology & Biomedical ImagingUniversity of California, San FranciscoSan Francisco, CaliforniaDavid E. Griffith, MD, ATSF, FACCP, FRSMProfessor of MedicineDivision of Mycobacterial and Respiratory DiseasesDepartment of MedicineNational Jewish HealthDenver, ColoradoProgram page: https://bit.ly/4mZbYsm

Listen in as Joseph Kim, MD, MPH, MBA, interviews Natalie, Orbach, PA-C, to learn about how she implemented patient-centered and individualized treatment plans to improve obesity care at her practice, includingDiscussing weight and how nutrition, physical activity, mental health, and pharmacotherapy strategies can helpMeeting patients where they are at and offering slow, incremental changes that support long-term outcomesReferring patients to community resources and other professionals as needSharing lessons learned for those interested in implementing similar strategies in their practice PresenterJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaNatalie Orbach, PA-CPhysician AssistantFeirtag & Ramos, PALutherville, Maryland Link to full program: https://bit.ly/45P0v8z

Listen as Michael S. Blaiss, MD provides case-based perspectives on chronic cough recognition, burden, management, and pathophysiology and describes the evolving treatment landscape for refractory chronic cough.PresenterMichael S. Blaiss, MDClinical Professor of PediatricsDivision of Allergy-ImmunologyMedical College of Georgia at Augusta UniversityAugusta, GeorgiaLink to full program: https://bit.ly/4kweynG

Listen in as Paula Henao, MD; Rohit Loomba, MD, MHSc; Cheryl Pirozzi, MD, MS; and Corinne Young, NP, FCCP, discuss their screening and monitoring strategies for patients with alpha-1 antitrypsin deficiency, including:Why early detection is key for improving patient outcomesHow to monitor through use of noninvasive imaging and biopsy per guideline recommendationsHow to coordinate patient care to provide much-needed multidisciplinary careWhat therapies in the pipeline could transform the treatment landscape for this genetic disease PresentersPaula Henao, MDAssistant Professor of MedicineDivision of Pulmonary, Allergy and Critical Care MedicinePenn State Hershey Medical CenterHershey, PennsylvaniaRohit Loomba, MD, MHScProfessor of MedicineChief, Division of Gastroenterology and HepatologyDirector, MASLD Research CenterUniversity of California, San DiegoSan Diego, CaliforniaCheryl Pirozzi, MD, MSAssociate Professor of Internal MedicineDivision of Pulmonary and Critical Care MedicineUniversity of UtahSalt Lake City, UtahCorinne Young, NP, FCCPPresident/FounderAssociation of Pulmonary Advanced Practice ProvidersColorado Springs, ColoradoLink to full program: https://bit.ly/4dgCRnq

Listen in as Joseph Kim, MD, MPH, MBA, interviews Sejal Desai, MD, DABOM, to learn about how she implemented virtual support groups to improve obesity care at her practice, including:Dedicating 5 support groups with chat features to obesity-specific topics (eg, sleep, nonscale wins)Moderating these chats to ensure no misinformation is shared and a positive, safe space is maintainedExpanding to include other virtual options that allow patients to engage more in their careUtilizing free and subscription-based services to aid in marketing effortsSharing lessons learned for those interested in implementing similar virtual options for their patients PresentersJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, PennsylvaniaSejal Desai, MD, DABOMBoard-Certified Obesity Medicine PhysicianOwner & Medical DirectorTula Medical Weight Loss & WellnessKaty, TexasLink to full program: https://clinicaloptions.com/content/qi-resource-hub

Listen in as Joseph Kim, MD, MPH, MBA, interviews Sophia Kwon, MD, to learn about how she implemented a documentation shortcut at her institution to improve obesity care, including:Creating an obesity checklist within the electronic health recordTraining staff to correctly use this checklist and broach obesity topics with patientsGarnering feedback to ensure this checklist did not add to note fatigue or burnout among staffSharing lessons learned for others interested in implementing a similar documentation shortcutPresenterJoseph Kim, MD, MPH, MBAPresidentQ Synthesis, LLCNewtown, Pennsylvania Sophia Kwon, MDInternal Medicine AttendingRiverside University Health System AttendingLoma Linda University Health Associate FacultyLoma Linda, California

In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:Disease concerns and frequently asked questions from a patient perspectiveManaging symptomsTreatment options and supportive careImportance of awareness and educationPresenters:Gideon Hirschfield, MA, MB BChir, FRCP, PhDLily and Terry Horner Chair in Autoimmune Liver Disease ResearchProfessor, Division of Gastroenterology and HepatologyUniversity of TorontoDirector, The Autoimmune and Rare Liver Disease ProgrammeDirector, Francis Family Liver ClinicToronto General Hospital, University Health NetworkOntario, CanadaJess N. Schnur, BSN-RNNational PBC Patient AdvocateAmerican Liver FoundationDonation Support Services CoordinatorLifeline of OhioColumbus, OhioTo learn more, see the program Hear Me: Patient Perspectives on PBC

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau, use an illustrative patient case to explore the roles of ALP and other biochemical markers in PBC management, and explain what to expect from treatment. Topics covered include: How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelparPotential outcomes if ALP normalization cannot be achievedThe importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical responsePresenters:Stuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MDProfessor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.  

In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients ​with cirrhosis. Topics covered include:AASLD guideline recommendations for second-line therapy for PBCConsiderations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelparPresenters:Stuart C. Gordon, MD Professor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganNancy Reau, MD Professor of MedicineRichard B. Capps Chair of HepatologyChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRush University Medical CenterChicago, IllinoisTo learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:Strategies and tools for assessing pruritusNonpharmacologic and pharmacologic management of pruritusSecond-line agents and their impact on pruritusInvestigational treatments for pruritusPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.

How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:How and when to measure treatment responseEvidence-based goals of therapyConsiderations for second-line treatmentNew agents for second-line treatment: PPAR agonistsPresenters:Alan Bonder, MD, AGAFAssociate Professor of MedicineMedical Director of Liver TransplantDepartment of GastroenterologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsAparna Goel, MDAssociate Clinical Professor of MedicineDivision of Gastroenterology and HepatologyStanford UniversityPalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc​.To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc

In this podcast, Sonal Kumar, MD, MPH, meets with patient advocate Maria Morais to discuss actionable steps that healthcare providers can incorporate into the care of people with primary biliary cholangitis (PBC). Listen as they discuss:The chronic nature of PBCGoing beyond biochemical markers to assess and address symptoms such as fatigue and pruritusThe importance of referral to patient support groupsPresenters:Sonal Kumar, MD, MPHAssistant Professor of MedicineDirector, General Gastroenterology and HepatologyWeill Cornell Medical CollegeNew York, New YorkMaria G. Morais, RNVP Patient AdvocacyCanadian PBC SocietyToronto, CanadaTo learn more, see the program Hear Me: Patient Perspectives on PBC

Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:The current treatment landscape (eg, small molecules, biologics)Risk factors to consider when prescribing JAK inhibitorsKey considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideation Nonpharmacologic options to improve treatment outcomesShared decision-making strategies to enhance patients' investment in their carePresenter:Alexis Ogdie, MD, MSCEDirector, Penn Psoriatic Arthritis and Spondylarthritis ProgramDirector, Penn Center for Clinical Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJulia Swafford, PA-C, DFAAPAPresident of SPARBronson Battle Creek Rheumatology SpecialistsBattle Creek, MichiganLink to full program:https://bit.ly/4gkTzSv

In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:ELATIVE, a phase III trial of elafibranor for PBCRESPONSE, a phase III trial of seladelpar for PBCASSURE, another phase III trial of seladelpar for PBCPresenter:Sonal Kumar, MD, MPHDirector, Clinical Gastroenterology and HepatologyAssistant Professor of MedicineWeill Cornell Medical CollegeNew York, New YorkLink to full program:https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Clinical gaps in the treatment of pruritus in primary biliary cholangitis (PBC) remain. In this episode, taken from a recent symposium, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss emerging therapies currently in clinical trials for the management of this disease that can dramatically affect patients' quality of life.Listen as they discuss:Gaps in current managementPatient perspectives: why we should not dismiss itching as an underlying psychologic problemPPAR agonists and how they affect pruritusBEZURSO and FITCH ELATIVEENHANCE and RESPONSEIBATs (inhibitors of bile acid transport)GLIMMERCommon questionsPresenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBCLink to full program: https://bit.ly/3Dnfb2E

Although there is currently no FDA-approved treatment for pruritus in primary biliary cholangitis (PBC), symptoms can be mitigated with nonpharmacologic or pharmacologic agents. In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss the clinical management of pruritus in PBC, including:Pruritus assessment toolsOptimal use of tools, including frequency of assessmentCurrent management of pruritusNonpharmacologic interventionsPharmacologic agentsStrategies to optimize assessment and management of pruritusCollaborative careDevelopment of a treatment planOngoing assessment and adjustment of therapyResources and support for patientsPresenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBCLink to full program: https://bit.ly/3Dnfb2E

In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with primary biliary cholangitis (PBC), discuss the burden of pruritus in PBC and the impact it has on quality of life, including both physical and mental health, from a patient's perspective. Presenters:Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasStuart C. Gordon, MDProfessor of MedicineWayne State University School of MedicineDirector, Division of HepatologyHenry Ford HealthDetroit, MichiganPam Rivard, RNPerson living with PBC Link to full program: https://bit.ly/4gDGDaB

In this episode, Christopher L. Bowlus, MD, discusses recent advances in the management of primary biliary cholangitis (PBC), including:Treatment goalsUse of PPAR agonists for the treatment of PBCClinical trial results for elafibranor (ELATIVE), seladelpar (RESPONSE), and bezafibrate (BEZURSO)Presenter:Christopher L. Bowlus, MDLena Valente Professor and ChiefDivision of Gastroenterology and HepatologyUniversity of California Davis School of MedicineSacramento, CaliforniaLink to full program: https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Listen as Elizabeth Kircher, DNP, and R. Hal Scofield, MD, discuss best practice approaches for the treatment of Sjögren's syndrome and what's on the horizon for future therapeutic options.Topics include:Challenges in Sjogren's Syndrome Diagnosis and Patient Understanding: Difficulties in explaining Sjogren's syndrome diagnosis to patients unfamiliar with it and challenges in addressing the disease's varied symptomsPatient Education and Communication: Strategies to prevent overwhelming patients during early visits and effective ways to address misconceptionsDiagnostic Challenges and Misunderstandings: Differences between clinical and research criteria for diagnosis and the importance of understanding eachUse of Ultrasound and Biopsy in Diagnosis: Benefits and limitations of ultrasound and biopsies in diagnosing Sjogren's syndromeMultidisciplinary Care Barriers: Challenges in coordinating care among specialists such as ophthalmologists, dentists, and rheumatologistsSymptomatic vs Disease-Modifying Treatments: Strategies for managing symptoms vs addressing the underlying disease with medicationsLong-term Medication and Risks: Considerations when prescribing long-term medications and immunosuppressive therapiesResearch and Emerging Therapies: Developments in Sjogren's syndrome research, including promising medications in clinical trialsGuideline Development and Patient Reassurance: The role of professional guidelines in shaping care and providing patients with reassurancePolypharmacy and Medication Reconciliation: The importance of pharmacist involvement in managing complex medication regimens for older patients Faculty:Elizabeth Kircher, DNPR. Hal Scofield, MDMember/Professor, Arthritis & Clinical ImmunologyOklahoma Medical Research FoundationProfessor, Department of Medicine, College of MedicineUniversity of Oklahoma Health Sciences CenterAssociate Chief of Staff for ResearchOklahoma City US Department of Veterans Affairs Medical CenterOklahoma City, OklahomaLink to full program:https://bit.ly/3YKpsOE

In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients' kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies.  Topics include:Supportive care as the foundation of IgAN managementPlace in therapy for new and emerging agentsTargeted-release formulation of budesonideEndothelin receptor antagonists (eg, sparsentan)Factor B inhibitors (eg, iptacopan)The role of clinical trial involvementLearn more about IgA nephropathy with educational activities and resources here:  CME-certified text module with animated pathophysiology video and patient voice audio clipClinicalThought commentariesResources on IgAN from the American Kidney Fund

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Colchicine: inhibition of NLRP3 inflammasome assembly/activationCanakinumab (anti–IL-1β monoclonal antibody)Ziltivekimab (anti–IL-6 monoclonal antibody)Other emerging targets/therapies To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.    Episode outline:   The relationship among systemic inflammation, ASCVD, and CKD The role of cardiologists and nephrologists in screening and mitigating systemic inflammation To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Moving beyond lipid lowering to address residual inflammatory riskNovel anti-inflammatory targets for ASCVD To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clipsClinicalThought commentariesPodcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases. Episode outline: Seeking and obtaining an IgAN diagnosis Patient self-advocacy Individualizing IgAN treatment plansClinical trial involvement Burdens of IgAN: physical, emotional, social, and beyondTo learn more about IgA nephropathy, find more educational activities and resources with the links below: CME-certified text module with animated pathophysiology video and patient voice audio clipsClinicalThought commentaries Resources on IgAN from the American Kidney Fund 

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies. Presenters:Arun B. Jesudian, MDAssociate Professor of Clinical MedicineDivision of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkMazen Noureddin, MD, MHScProfessor of MedicineHouston Methodist HospitalDirector Houston Research InstituteHouston, TexasContent based on an online CME program supported by independent educational grants from Novo Nordisk.To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.Link to full program:https://bit.ly/3Tyu7At

In this episode, Jennifer Green, MD, and Carol Hatch Wysham, MD, break down the latest headlines on incretin-based therapies and how to address these topics with patients. Their discussion includes:Beneficial effects beyond glycemic control Adverse events and how to manage themNon- or partial responders and the importance of setting expectations with patients Weight rebound when discontinuing therapyMedication access issues related to cost and drug availability Presenters:Jennifer Green, MDProfessor of MedicineDivision of Endocrinology and Duke Clinical Research InstituteDuke University School of MedicineDurham, North CarolinaCarol Hatch Wysham, MDClinical Professor of MedicineClinical EndocrinologistMultiCare/Rockwood ClinicSpokane, WashingtonLink to online program: https://bit.ly/48b6XnW

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screeningPresenters:Douglas Dieterich, MDDirector, Institute for Liver MedicineProfessor of MedicineDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkCamilla S. Graham, MD, MPHCo-Director, Viral Hepatitis ClinicDivision of Infectious DiseasesBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsRobert Wong, MD, MS Clinical Associate ProfessorDivision of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaLink to full program:https://bit.ly/3TuqFHILink to the slides: https://bit.ly/4atS42z

In this podcast episode, Aline Charabaty, MD, AGAF, FACG, and Marla Dubinsky, MD, discuss how women in gastroenterology (GI) can find their “friendtors” and build a strong network of mentors, sponsors, and allies. Although there may be many barriers for women in the GI medicine specialty, these experienced leaders have useful tips to help emerging healthcare professionals avoid internalizing these challenges and strategically focus on accomplishing their goals.  Presenters:  Dr Aline Charabaty is an Assistant Professor of Medicine at Johns Hopkins School of Medicine, the Clinical Director of the IBD Centre at Johns Hopkins Sibley Memorial Hospital in Washington, DC, and the Co-Founder of Scrubs & Heels.  Aline Charabaty, MD, AGAF, FACG: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda.Dr Marla Dubinsky is a Professor of Pediatrics and Medicine at Mount Sinai in New York, Chief of Division of Pediatric GI and Nutrition at Mount Sinai Kravis Children's Hospital, and the Co-Director of the Susan and Leonard Feinstein IBD Clinical Centre. Dr Dubinsky is also the Director of the Marie and Barry Lipman IBD Preconception and Pregnancy Clinic. She is also an innovator and the Co-Founder of Trellus Health, providing personalized resilience coaching for people living with IBD. She received the Sherman Prize in 2022, which recognized her outstanding achievement in the field of IBD. In addition, she served as the Co-Chair for our inaugural Scrubs & Heels Leadership Summit in 2022.  Marla Dubinsky, MD: consultant/advisor/speaker: AbbVie, Abivax, AstraZeneca, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer, Prometheus Biosciences, Takeda.Episode outline: Overview of barriers faced by women in GIImpact of failing to adequately address these barriersDefining the roles of mentors, sponsors, and alliesImportant qualities of mentors, sponsors, and alliesRole models vs peer mentorsOther program activities: Full Program: Equipped and Empowered: Thriving as Women in GIPodcast 2: Embracing Your Value: Tools and Strategies for Optimizing Professional Growth and DevelopmentPodcast 3: Being Your Full Self: Pursuing Work–Life BalanceClinicalThought: Expert Commentary on Thriving as Women in GIAfter selecting the “Continue to Post Test” button:To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom

In this podcast episode, Anita Afzali, MD, MPH, MHCM, FACG, AGAF, and Aja McCutchen, MD, discuss how women in gastroenterology (GI) can embrace and enhance their value. These inspiring GI medicine experts propose a practical formula that involves ongoing, careful self-reflection and asking yourself how your strengths, core values, and interests can be aligned with professional endeavors. In addition, self-advocacy and self-allyship can serve as harmonious tools to drive action and positive change.   Presenters:Dr Anita Afzali is a Professor of Clinical Medicine, Interim Division Director of the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine, and the Associate Chief Medical Officer of the UC Health system in Cincinnati, Ohio. She is also a Co-Founder of Scrubs & Heels.Anita Afzali, MD, MPH, MHCM, FACG, AGAF: consultant: AbbVie, Bristol Myers Squibb, Gilead Sciences, Janssen, Lilly, Pfizer, Takeda; provider of non-CME/CE services: AbbVie, Janssen, Pfizer, Takeda.Dr Aja McCutchen is a Partner and Physician Executive at Atlanta Gastroenterology Associates, a division of United Digestive in Atlanta, Georgia, and served as Co-Chair at the Scrubs & Heels 2023 Leadership Summit. Aja McCutchen, MD: consultant/advisor/speaker: Eli Lilly, Modify Health, Redhill Biopharm, Sanofi Regeneron, Takeda.Episode outline: Understanding and establishing your own market value; bringing that to your own organizationConsequences of being ill-equipped to pursue professional growth and developmentAdvocating for the value you bring to the professionNegotiation as a form of self-allyshipNegotiation categories to help support career success and protect work–life balanceOther program activities: Full Program: Equipped and Empowered: Thriving as Women in GIPodcast 1: Finding Your Friendtors: Mentors, Sponsors, and AlliesPodcast 3: Being Your Full Self: Pursuing Work–Life BalanceClinicalThought: Expert Commentary on Thriving as Women in GITo receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom.

In this podcast episode, Aline Charabaty, MD, AGAF, FACG, and Christina Tennyson, MD, DipABLM, discuss how women in gastroenterology (GI) can fight burnout and establish a work–life balance that meets their needs. Tune in to learn how to say no, about the importance of saying yes to meaningful things that will advance your career and bring you joy, and get essential tips for well-rounded and ongoing self-care.     Presenters:Dr Aline Charabaty is an Assistant Professor of Medicine at Johns Hopkins School of Medicine, the Clinical Director of the IBD Centre at Johns Hopkins Sibley Memorial Hospital in Washington, DC, and the Co-Founder of Scrubs & Heels. Aline Charabaty, MD, AGAF, FACG: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Takeda.Dr Christina Tennyson is a gastroenterologist with expertise and certification in nutrition, lifestyle medicine, and integrative medicine. She started her career in academia at Columbia University in New York before joining the Augusta Health Digestive Wellness program in the Virginia Shenandoah Valley, where she is engaged in a multidisciplinary program that includes culinary medicine classes and farm workshops for patients. Christina Tennyson, MD, DipABLM, has no relevant financial relationships to disclose.[Link to: https://scrubsandheels.com/] Episode outline: Variables that contribute to burnoutStrategies to protect your timeVetting collaborative projectsRequesting flexible schedules, part-time work, maternity leaveCharting your own career pathPrioritizing personal timePreserving friendships, hobbiesLeave work at workOther program activities: Full Program: Equipped and Empowered: Thriving as Women in GI https://bit.ly/3Zmqy1I]Podcast 1: Finding Your Friendtors: Mentors, Sponsors, and Allies https://bit.ly/3LuKzO6Podcast 2: Embracing Your Value: Tools and Strategies for Optimizing Professional Growth and Development https://bit.ly/3RsFl9iClinicalThought: Expert Commentary on Thriving as Women in GI https://bit.ly/48oi5iSLink to CME: Claim Credit: https://bit.ly/48oi5iS[After selecting the “Continue to Post Test” button:]To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select 1 best answer for each question. When you have completed all the questions, press the "Continue" button at the bottom.

This podcast episode is part of a multimedia program discussing the impact of health disparities in anemia of chronic kidney disease (CKD) on patient outcomes. Tune in to hear Santosh Saraf, MD, and Milda Saunders, MD, MPH, highlight mitigation strategies to improve screening and management. The overview will include: The definition of CKD and the relative prevalence in specific minority groupsHow health disparities affect CKD-related clinical and patient outcomesAppropriate screening techniques to diagnose patients with anemia of CKDStrategies to address health disparities to improve patient outcomes in the management of anemia of CKDPresenters: Santosh Saraf, MDAssociate Professor of MedicineDivision of Hematology and OncologyDepartment of MedicineUniversity of Illinois at ChicagoChicago, Illinois  Milda Saunders, MD, MPHAssociate Professor of MedicineDepartment of MedicineUniversity of ChicagoChicago, IllinoisTo view other program offerings, including a CE-certified on-demand webcast, a ClinicalThought commentary, and to download slides, visit:https://bit.ly/3iL07S0

In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis.Presenters: Karen H. Costenbader, MD, MPHProfessor of MedicineDepartment of MedicineHarvard Medical SchoolDirector, Lupus ProgramDivision of Rheumatology, Inflammation and ImmunityBrigham and Women's HospitalBoston, MassachusettsBrad H. Rovin, MDProfessor and Director, Division of NephrologyThe Lee A. Hebert Professor of NephrologyMedical Director, The Ohio State Center for Clinical Research ManagementThe Ohio State University Wexner Medical CenterColumbus, OhioReview the downloadable slidesets at: https://bit.ly/3mlHOlaLink to full program:https://bit.ly/3aC2NNL

In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHAProfessor of Medicine Tulane Heart and Vascular InstituteTulane University School of MedicineNew Orleans, LouisianaDavid S. Kountz, MDProfessor of MedicineDepartment of MedicineHackensack Meridian School of MedicineNutley, New JerseyLink to full program:https://bit.ly/3MbIfZI

In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes.PresentersKeith C. Ferdinand, MD, FACC, FAHA Professor of Medicine Tulane Heart and Vascular InstituteTulane University School of MedicineNew Orleans, LouisianaDavid S. Kountz, MDProfessor of MedicineDepartment of MedicineHackensack Meridian School of MedicineNutley, New JerseyLink to full program: https://bit.ly/3MbIfZI

In this episode, Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, discuss health disparities in systemic lupus erythematosus and lupus nephritis. Topics include: Disproportionate prevalence among marginalized groups in the United StatesLupus-related social determinants of healthChallenges with medication adherenceStrategies to reduce these disparitiesPresenters:Karen H. Costenbader, MD, MPHProfessor of MedicineDepartment of MedicineHarvard Medical SchoolDirector, Lupus ProgramDivision of Rheumatology, Inflammation and ImmunityBrigham and Women's HospitalBoston, MassachusettsBrad H. Rovin, MDProfessor and Director, Division of NephrologyThe Lee A. Hebert Professor of NephrologyMedical Director, The Ohio State Center for Clinical Research ManagementThe Ohio State University Wexner Medical CenterColumbus, OhioThis episode is part of a larger program titled, “Lupus and Lupus Nephritis: Improving Outcomes and Reducing Disparities.” To access the full program, follow this link: https://bit.ly/3PWAzNU

This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.Review the downloadable slideset and the full program at: https://bit.ly/3yYXP8e

This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcomes in NVAF.Review the downloadable slideset and the full program at:   https://bit.ly/3yYXP8e